Comparative Pharmacology
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus BETOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus BETOPTIC.
BETAXOLOL HYDROCHLORIDE vs BETOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
10-20 mg orally once daily; maximum 20 mg/day.
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
None Documented
None Documented
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data.
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites.
Category C
Category C
Beta-Blocker
Beta-Blocker